Fate Therapeutics, Inc. (FATE) AI Stock Analysis

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops programmed cellular immunotherapies designed to treat cancer and immune disorders. Its pipeline focuses on off-the-shelf natural killer (NK) and T-cell immuno-oncology programs. Key clinical candidates include FT516, FT596, FT538, FT576, FT819, FT536, and FT500, targeting hematologic malignancies such as acute myeloid leukemia, B-cell lymphoma, and multiple myeloma, as well as advanced solid tumors. To advance its research and development, Fate Therapeutics maintains strategic collaborations with Ono Pharmaceutical Co. Ltd., Juno Therapeutics, Inc., and Janssen Biotech, Inc.

Revenue has contracted significantly after reaching $96.3M in FY2022. Revenue fell 34.0% to $63.5M in FY2023, dropped 78.5% to $13.6M in FY2024, and declined 51.2% to $6.6M in FY2025. Over the five years from FY2020 to FY2025, revenue posted a compound annual growth rate of -26.7%. Operating margin was -2222.4% in FY2025, with research and development expenses totaling $107.8M. Annual net losses were -$136.3M in FY2025, or an EPS of -$1.15, following a net loss of -$186.3M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue grew 9.2% year-over-year, while trailing twelve-month revenue stood at $6.5M with an operating margin of -1495.4%.

As of June 30, 2026, Fate Therapeutics had $153.8M in cash and short-term investments against total debt of $75.7M, yielding net cash of $78.1M. Shareholders' equity was $153.4M and total assets were $260.1M. The company maintained a current ratio of 4.85 and a debt-to-equity ratio of 0.49. In FY2025, operating cash flow was -$106.1M and capital expenditures were $6.0M, resulting in free cash flow of -$112.0M. The company does not repurchase shares, though its share count increased 25.7% over five years.

With a market capitalization of $214.5M and an enterprise value of $213.7M, Fate Therapeutics trades at a price-to-sales multiple of 33.0x and an EV-to-revenue multiple of 32.9x. These figures trade at a premium to the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x. The stock trades at a price-to-book ratio of 1.9x. Over the past year, FATE shares gained 16.2%, trailing the 16.8% return of the S&P 500 benchmark. Over five years, the stock fell 97.1%, compared to an 83.0% gain for the benchmark.

Wall Street coverage on FATE consists of 4 Strong Buy, 1 Buy, and 6 Hold ratings, with zero Sell or Strong Sell ratings. The mean analyst price target is $5.74, representing an upside of 220.9% above the last close of $1.79. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $5.6M and an EPS of -$1.02. For the following fiscal year, 8 analysts estimate revenue of $4.8M and an EPS of -$0.97. Fate Therapeutics beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Fate Therapeutics, Inc. (FATE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: FATE income statement, FATE balance sheet, FATE key metrics, FATE analyst forecast, FATE chart. See the FATE stock overview for the latest quote and news.